A Dual-Antigen Enzyme-Linked Immunosorbent Assay Allows the Assessment of Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Seroprevalence in a Low-Transmission Setting

    Thumbnail
    Citations
    Scopus
    Web of Science
    Altmetric
    7
    3
    Author
    Hicks, SM; Pohl, K; Neeman, T; McNamara, HA; Parsons, KM; He, J-S; Ali, SA; Nazir, S; Rowntree, LC; Nguyen, THO; ...
    Date
    2021-01-01
    Source Title
    Journal of Infectious Diseases
    Publisher
    OXFORD UNIV PRESS INC
    University of Melbourne Author/s
    Rowntree, Louise; Kedzierska, Katherine; Nguyen, Thi Hoang Oanh; George, Amee
    Affiliation
    Microbiology and Immunology
    Clinical Pathology
    Metadata
    Show full item record
    Document Type
    Journal Article
    Citations
    Hicks, S. M., Pohl, K., Neeman, T., McNamara, H. A., Parsons, K. M., He, J. -S., Ali, S. A., Nazir, S., Rowntree, L. C., Nguyen, T. H. O., Kedzierska, K., Doolan, D. L., Vinuesa, C. G., Cook, M. C., Coatsworth, N., Myles, P. S., Kurth, F., Sander, L. E., Mann, G. J. ,... Cockburn, I. A. (2021). A Dual-Antigen Enzyme-Linked Immunosorbent Assay Allows the Assessment of Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Seroprevalence in a Low-Transmission Setting. JOURNAL OF INFECTIOUS DISEASES, 223 (1), pp.10-14. https://doi.org/10.1093/infdis/jiaa623.
    Access Status
    Access this item via the Open Access location
    URI
    http://hdl.handle.net/11343/254463
    DOI
    10.1093/infdis/jiaa623
    Open Access URL
    Published version
    Open Access at PMC
    http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665523
    Abstract
    Estimates of seroprevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies have been hampered by inadequate assay sensitivity and specificity. Using an enzyme-linked immunosorbent assay-based approach that combines data about immunoglobulin G responses to both the nucleocapsid and spike receptor binding domain antigens, we show that excellent sensitivity and specificity can be achieved. We used this assay to assess the frequency of virus-specific antibodies in a cohort of elective surgery patients in Australia and estimated seroprevalence in Australia to be 0.28% (95% Confidence Interval, 0-1.15%). These data confirm the low level of transmission of SARS-CoV-2 in Australia before July 2020 and validate the specificity of our assay.

    Export Reference in RIS Format     

    Collections